Stocks, Forex, Bonds, Indices, Commodities. World Financial Markets.
The Top Holistic Analysis Site.
Learning to be successful means learning from the successful people how they breathe, how they think and how they translate thoughts into actions.
- Donovan Norfolk
Click "Like" to Receive First Hand Updates From The Analysis Site / Click "SHARE" to share
Tuesday, 30 January 2018
Exelixis Inc (NASD: EXEL): 30 January 2018, Tuesday, 3.28pm Singapore Time
Exelixis Inc (NASD: EXEL):
30 January 2018, Tuesday, 3.28pm Singapore Time
(Click on Technical Chart above to Expand)
Attached above is the technicals for Exelixis, a company that is listed in the NASDAQ. Exelixis is a genomics-based drug discovery company, and the producer of Cometriq, a treatment approved by the FDA for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. It holds a number of high value biomedical patents. The orange region shows the first high volume absorption of Exelixis at $24 region. Blue circled regions are the deliberate volume absorptions at $23-$28 region. Green circled regions are impulsive buys at $25-$28 region. Fellow smart monies in Wall Street have a lot of deliberate buys on Exelixis at $23-$28 region in conclusion. We are currently not far from their buys. Expect +100% upside from this stock. This stock is supported with moving average rising uptrends.
The Donovan Norfolk Technical Rating: Very Bullish (Strong Buy)